The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 ...

GLP-1: Glucagon-like peptide-1 ... GLP1-RAs result in an associated increased risk of pancreatitis or medullary thyroid carcinoma. Development of antidrug antibodies are common with the LA ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The Medicines and Healthcare Products Regulatory Agency (MHRA) has ruled that warnings about the risk should now be added to drugs like Ozempic, Wegovy and Mounjaro.

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...